| 1.31 -0.01 (-0.76%) | 11-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.83 | 1-year : | 2.14 |
| Resists | First : | 1.57 | Second : | 1.83 |
| Pivot price | 1.28 |
|||
| Supports | First : | 1.22 | Second : | 1 |
| MAs | MA(5) : | 1.34  |
MA(20) : | 1.29 |
| MA(100) : | 0.84 |
MA(250) : | 0.67 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 63 |
D(3) : | 71 |
| RSI | RSI(14): 53.2 |
|||
| 52-week | High : | 1.57 | Low : | 0.37 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TLPH ] has closed below upper band by 42.8%. Bollinger Bands are 19.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.39 - 1.4 | 1.4 - 1.41 |
| Low: | 1.28 - 1.29 | 1.29 - 1.29 |
| Close: | 1.3 - 1.31 | 1.31 - 1.32 |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
Thu, 13 Nov 2025
Talphera, Inc. Earnings Call: Balancing Achievements and Challenges - The Globe and Mail
Wed, 12 Nov 2025
Talphera Inc (TLPH) Q3 2025 Earnings Call Highlights: Strategic Investments and Regulatory ... - Yahoo Finance
Tue, 11 Nov 2025
Earnings Outlook For Talphera - Benzinga
Thu, 16 Oct 2025
Talphera appoints Joseph Todisco to board, grants CorMedix board designation rights - Investing.com
Mon, 08 Sep 2025
Talphera (TLPH) Secures $29 Million Investment through Private P - GuruFocus
Mon, 08 Sep 2025
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 1.276e+007 (%) |
| Held by Institutions | 28.4 (%) |
| Shares Short | 799 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -49 % |
| Return on Assets (ttm) | 459.2 % |
| Return on Equity (ttm) | -40.4 % |
| Qtrly Rev. Growth | 27000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -470.24 |
| EBITDA (p.s.) | -2.408e+007 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.02 |
| Dividend | 0 |
| Forward Dividend | 1.79e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|